35
Participants
Start Date
May 29, 2013
Primary Completion Date
September 2, 2015
Study Completion Date
April 28, 2016
Nilotinib
Tasigna®(nilotinib):: 50 mg, 150 mg and 200 mg capsules. Tasigna® capsules contain lactose monohydrate, crospovidone, poloxamer, colloidal silicon dioxide and magnesium. Orally; the capsules should be swallowed as a whole with water. No food should be consumed for 2 hours before the dose is taken and for at least one hour thereafter. For patients who are unable to swallow capsules, the content of each capsule may be dispersed in one teaspoon of apple sauce or compote or nonfat plain yogurt and should be taken immediately. Not more than one teaspoon of apple sauce / yogourt, and no food other than apple sauce or nonfat plain yogurt must be used.
Vinblastine
"Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle.~Each 28-day cycle is repeated on Day 29/Day 1. No intra-patient doseescalation is permitted. Dose allocation will be centrally defined, based on toxicity observed in patients previously evaluated. Every new patient will be treated at the best current recommended dose, i.e. the dose associated with an estimated level of toxicity that is judged acceptable (20% DLT). At least two patients fully observed with no DLT are requested at a given dose level before dose escalation."
Swiss Pediatric Oncology Group, Bern
University Hospital of Padua, Padua
Gustave Roussy, Villejuif
Medical University of Vienna, Vienna
Rigshospitalet, Copenhagen
Erasmus MC/Sophia Children's Hospital, Rotterdam
Fundació Sant Joan de Déu, Barcelona
Cancer Research UK Clinical Trials Unit School of Cancer Sciences University of Birmingham, Edgbaston
Gustave Roussy, Cancer Campus, Grand Paris
OTHER